Tratamiento oncológico del angiosarcoma cutáneo. Revisión de la literatura

Mobini N. Cutaneous epithelioid angiosarcoma: a neoplasm with potential pitfalls in diagnosis. J Cutan Pathol. 2009;36:362-9.

https://doi.org/10.1111/j.1600-0560.2008.01052.x

Holden CA, Spittle MF, Jones EW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer. 1987;59:1046-57.

https://doi.org/10.1002/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO;2-6

Pawlik TM, Paulino AF, McGinn CJ, et al. Cutaneous angiosarcoma of the scalp: a multidisciplinary approach. Cancer. 2003;98:1716-26.

https://doi.org/10.1002/cncr.11667

Morrison WH, Byers RM, Garden AS, et al. Cutaneous angiosarcoma of the head and neck: a therapeutic dilemma. Cancer. 1995;76:319-27.

https://doi.org/10.1002/1097-0142(19950715)76:2<319::AID-CNCR2820760224>3.0.CO;2-8

Sasaki R, Soejima T, Kishi K, et al. Angiosarcoma treated with radiotherapy: impact of tumor type and size on outcome. Int J Radiat Oncol Biol Phys. 2002;52:1032-40.

https://doi.org/10.1016/S0360-3016(01)02753-5

Alessi E, Sala F, Berti E. Angiosarcomas in lymphedematous limbs. Am J Dermatopathol. 1986;8:371-8.

https://doi.org/10.1097/00000372-198610000-00002

Stewart FW, Treves N. Classics in oncology: lymphan-giosarcoma in postmastectomy lymphedema: a report of six cases in elephantiasis chirurgica. CA Cancer J Clin. 1981;31:284-99.

https://doi.org/10.3322/canjclin.31.5.284

Marchal C, Weber B, de Lafontan B, et al. Nine breast angiosarcomas after conservative treatment for breast carcinoma: a survey from French comprehensive cancer centers. Int J Radiat Oncol Biol Phys. 1999;44:113-9.

https://doi.org/10.1016/S0360-3016(98)00537-9

Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231-7.

https://doi.org/10.1016/S0360-3016(01)02799-7

Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241-7.

https://doi.org/10.1097/00130404-200505000-00011

Mark RJ, Poen JC, Tran LM, et al. Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996;77:2400-6.

https://doi.org/10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-Z

Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007;18:2030-6.

https://doi.org/10.1093/annonc/mdm381

Mendenhall WM, Mendenhall CM, Werning JW et al. Cutaneous angiosarcoma. Am J Clin Oncol. 2006;29:524-8.

https://doi.org/10.1097/01.coc.0000227544.01779.52

Penel N, Grosjean J, Robin YM, et al. Frequency of certain established risk factors in soft tissue sarcomas In adult: a prospective descriptive study of 658 cases. Sarcoma. 2008;2008:459386.

https://doi.org/10.1155/2008/459386

Costache M, Ene A, Simionescu O, et al. Histopathological diagnosis of cutaneous vascular sarcomas. Rom J Morphol Embryol. 2010;51:105-9.

Amo Y, Masuzawa M, Hamada Y, et al. Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients. Br J Dermatol. 2004;150:160-1.

https://doi.org/10.1111/j.1365-2133.2004.05751.x

Amo Y, Masuzawa M, Hamada Y, et al. Observations on angiopoietin 2 in patients with angiosarcoma. Br J Dermatol. 2004;150:1028-9.

https://doi.org/10.1111/j.1365-2133.2004.05932.x

Dim D, Ravi V, Tan J, et al. The actin-bundling motility protein fascin and vascular endothelial growth factor (VEGF) are universally over-expressed in human angiosarcoma. Proc Am Soc Clin Oncol. 2007;25:10068.

Itakura E, Yamamoto H, Oda Y, et al. Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. J Surg Oncol. 2008;97:74-81.

https://doi.org/10.1002/jso.20766

Zietz C, Rumpler U, Sturzl M, et al. Inverse relation of Fasligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am J Pathol. 2001;159:963-70.

https://doi.org/10.1016/S0002-9440(10)61772-5

Yamamoto T, Umeda T, Nishioka K. Immunohistological distribution of stem cell factor and kit receptor in angiosarcoma. Acta Derm Venereol. 2000;80:443-5.

https://doi.org/10.1080/000155500300012954

Isoda H, Imai M, Inagawa S, et al. Magnetic resonance imaging findings of angiosarcoma of the scalp. J Comput Assist Tomogr. 2005;29:858-62.

https://doi.org/10.1097/01.rct.0000183274.70422.0a

Edge SB, Byrd DR, Compton CC, et al., editors. AJCC Cancer Staging Manual, 7th ed. New York: Springer; 2010. pp. 291-8. 24. Naka N, Ohsawa M, Tomita Y, et al. Prognostic factors in angiosarcoma: a multivariate analysis of 55 cases. J Surg Oncol. 1996;61:170-6.

https://doi.org/10.1002/(SICI)1096-9098(199603)61:3<170::AID-JSO2>3.0.CO;2-8

Abraham JA, Hornicek FJ, Kaufman AM, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007;14:1953-67.

https://doi.org/10.1245/s10434-006-9335-y

Casali PG, Jost L, Sleijfer S, et al. On behalf of the ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:89-93.

https://doi.org/10.1093/annonc/mdn101

Girard C, Johnson WC, Graham JH. Cutaneous angiosarcoma. Cancer. 1970;26:868-83.

https://doi.org/10.1002/1097-0142(197010)26:4<868::AID-CNCR2820260421>3.0.CO;2-L

Wilson-Jones E. Malignant angioendothelioma of the skin. Br J Dermatol. 1964;76:21-39.

https://doi.org/10.1111/j.1365-2133.1964.tb13970.x

DeMartelaere SL, Roberts D, Burgess M, et al. Neoadjuvant chemotherapy-specific and overall treatment outcomes in patients with cutaneous angiosarcoma of the face with periorbital involvement. Head Neck. 2008;30:639-46.

https://doi.org/10.1002/hed.20757

Casper ES, Waltzman RJ, Schwartz GK, et al. Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. 1998;16:442-6.

https://doi.org/10.3109/07357909809011697

Fata F, O'Reilly E, Ilson D, et al. Placitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer. 1999;86:2034-7.

https://doi.org/10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.0.CO;2-P

Verleysen A, Dewolf K, Geerts ML, et al. Angiosarcoma of the face and scalp. Eur J Dermatol. 2000;10:403-4.

Nagano T, Yamada Y, Ikeda T, et al. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer. 2007;110:648-51.

https://doi.org/10.1002/cncr.22822

Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26:5269-74.

https://doi.org/10.1200/JCO.2008.17.3146

Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer. 2005;104:361-6.

https://doi.org/10.1002/cncr.21140

Young RJ, Brown NJ, Reed MW, et al. Angiosarcoma Lancet Oncol. 2010;11:983-91.

https://doi.org/10.1016/S1470-2045(10)70023-1

AgulnikM,OkunoSH,VonMehrenM,etal.Anopen-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol. 2009;27(Suppl):10522.

Maki RG, D'Adamo DR, Keohan ML, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133-40.

https://doi.org/10.1200/JCO.2008.20.4495

Ryan CW, von Mehren M, Rankin JC, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. Proc Am Soc Clin Oncol 2008;26:10532.

https://doi.org/10.1200/jco.2008.26.15_suppl.10532

George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27:3154-60.

https://doi.org/10.1200/JCO.2008.20.9890

Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of Imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148-53.

https://doi.org/10.1200/JCO.2008.20.5054

Burns BT, Blakey SA, Harris WB. Complete response of metastatic angiosarcoma to liposomal doxorubicin and interferon-2a. Proc Am Soc Clin Oncol. 2002;21:2939.

Ohguri T, Imada H, Nomoto S, et al. Angiosarcoma of the scalp treated with curative radiotherapy plus recombinant interleukin-2 immunotherapy. Int J Radiat Oncol Biol Phys. 2005; 61:1446-53.

https://doi.org/10.1016/j.ijrobp.2004.08.008